Chemotherapy for treatment of grade II gliomas

Research output: Contribution to journalArticle

Abstract

Gliomas classified as grade II by the World Health Organization (WHO) include astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. This heterogeneous group of conditions is associated with a more favorable prognosis and longer-term survival than high-grade gliomas (HGGs). Neurosurgical resection and radiation therapy improve survival in symptomatic, progressive, or high-risk grade II gliomas. Until recently, the role of chemotherapy has been less clear. This review draws on insights from the management of HGGs and emerging data on the addition of PCV (procarbazine, lomustine [CCNU], and vincristine) to radiation for these neoplasms. Specifically, this review focuses on the current status of chemotherapeutic management of grade II gliomas, including optimal timing of treatment, and management of 1p19q codeleted and non-codeleted tumors.

Original languageEnglish (US)
Pages (from-to)1036-1043
Number of pages8
JournalOncology
Volume28
Issue number12
StatePublished - Dec 1 2014

Fingerprint

Glioma
Drug Therapy
Lomustine
Astrocytoma
Procarbazine
Therapeutics
Oligodendroglioma
Vincristine
Neoplasms
Radiotherapy
Radiation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chemotherapy for treatment of grade II gliomas. / Strowd, Roy E.; Holdhoff, Matthias; Grossman, Stuart A.

In: Oncology, Vol. 28, No. 12, 01.12.2014, p. 1036-1043.

Research output: Contribution to journalArticle

Strowd, Roy E. ; Holdhoff, Matthias ; Grossman, Stuart A. / Chemotherapy for treatment of grade II gliomas. In: Oncology. 2014 ; Vol. 28, No. 12. pp. 1036-1043.
@article{34c47f2c0adf47abb6fb68fbf02c113e,
title = "Chemotherapy for treatment of grade II gliomas",
abstract = "Gliomas classified as grade II by the World Health Organization (WHO) include astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. This heterogeneous group of conditions is associated with a more favorable prognosis and longer-term survival than high-grade gliomas (HGGs). Neurosurgical resection and radiation therapy improve survival in symptomatic, progressive, or high-risk grade II gliomas. Until recently, the role of chemotherapy has been less clear. This review draws on insights from the management of HGGs and emerging data on the addition of PCV (procarbazine, lomustine [CCNU], and vincristine) to radiation for these neoplasms. Specifically, this review focuses on the current status of chemotherapeutic management of grade II gliomas, including optimal timing of treatment, and management of 1p19q codeleted and non-codeleted tumors.",
author = "Strowd, {Roy E.} and Matthias Holdhoff and Grossman, {Stuart A}",
year = "2014",
month = "12",
day = "1",
language = "English (US)",
volume = "28",
pages = "1036--1043",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "12",

}

TY - JOUR

T1 - Chemotherapy for treatment of grade II gliomas

AU - Strowd, Roy E.

AU - Holdhoff, Matthias

AU - Grossman, Stuart A

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Gliomas classified as grade II by the World Health Organization (WHO) include astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. This heterogeneous group of conditions is associated with a more favorable prognosis and longer-term survival than high-grade gliomas (HGGs). Neurosurgical resection and radiation therapy improve survival in symptomatic, progressive, or high-risk grade II gliomas. Until recently, the role of chemotherapy has been less clear. This review draws on insights from the management of HGGs and emerging data on the addition of PCV (procarbazine, lomustine [CCNU], and vincristine) to radiation for these neoplasms. Specifically, this review focuses on the current status of chemotherapeutic management of grade II gliomas, including optimal timing of treatment, and management of 1p19q codeleted and non-codeleted tumors.

AB - Gliomas classified as grade II by the World Health Organization (WHO) include astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. This heterogeneous group of conditions is associated with a more favorable prognosis and longer-term survival than high-grade gliomas (HGGs). Neurosurgical resection and radiation therapy improve survival in symptomatic, progressive, or high-risk grade II gliomas. Until recently, the role of chemotherapy has been less clear. This review draws on insights from the management of HGGs and emerging data on the addition of PCV (procarbazine, lomustine [CCNU], and vincristine) to radiation for these neoplasms. Specifically, this review focuses on the current status of chemotherapeutic management of grade II gliomas, including optimal timing of treatment, and management of 1p19q codeleted and non-codeleted tumors.

UR - http://www.scopus.com/inward/record.url?scp=84925370680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925370680&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 1036

EP - 1043

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 12

ER -